Dr. Michael Sebag has been working towards improving the lives of patients with Multiple Myeloma (MM) and related disorders since 2006.
His focus has been on the preclinical development of novel drugs that target largely unexploited pathways in MM. In collaboration with medicinal chemistry at McGill, his team has developed completely new and interesting molecules that are at various stages of testing and development. His clinical focus has been on early phase, first in human clinical trials in MM. In addition, he is involved in the development of investigator-led clinical trials that are conducted across Canada. As the director of the McGill Immune Effector Cell program, he is also planning to bring exciting new therapies to patients with MM and other hematologic malignancies.